2 Infectious Diseases in Obstetrics and Gynecology As access to both modern methods of contraception and antiretroviral drugs

Background. Preventing unintended pregnancy in HIV-positive women can significantly reduce maternal-to-child HIV transmission as well as improve the woman’s overall health. Hormonal contraceptives are safe and effective means to avoid unintended pregnancy, but there is concern that coadministration of antiretroviral drugs may alter contraceptive efficacy. Materials and Methods. We performed a literature search of PubMed and Ovid databases of articles published between January 1980 and February 2012 to identify English-language reports of drug-drug interactions between hormonal contraceptives (HCs) and antiretroviral drugs (ARVs). We also reviewed the FDA prescribing information of contraceptive hormone preparations and antiretrovirals for additional data and recommendations. Results. Twenty peer-reviewed publications and 42 pharmaceutical package labels were reviewed. Several studies of combined oral contraceptive pills (COCs) identified decreased serum estrogen and progestin levels when coadministered with certain ARVs. The contraceptive efficacy of injectable depot medroxyprogesterone acetate (DMPA) and the levonorgestrel intrauterine system (LNG-IUS) were largely unaffected by ARVs, while data on the contraceptive patch, ring, and implant were lacking. Conclusions. HIV-positive women should be offered a full range of hormonal contraceptive options, with conscientious counseling about possible reduced efficacy of COCs and the contraceptive implant when taken with ARVs. DMPA and the LNG-IUS maintain their contraceptive efficacy when taken with ARVs.

[1]  J. Trussell,et al.  Emergency Contraception: A Last Chance to Prevent Unintended Pregnancy , 2014 .

[2]  A. Benachi,et al.  Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. , 2012, Contraception.

[3]  S. Quah,et al.  Implanon® failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies , 2011, International journal of STD & AIDS.

[4]  J. Wagner,et al.  Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. , 2011, British journal of clinical pharmacology.

[5]  Shaloo Gupta,et al.  Factors Associated with Complete Adherence to HIV Combination Antiretroviral Therapy , 2011, HIV clinical trials.

[6]  J. Park,et al.  Contraceptive Efficacy of Oral and Transdermal Hormones When Co-Administered With Protease Inhibitors in HIV-1-Infected Women: Pharmacokinetic Results of ACTG Trial A5188 , 2010, Journal of acquired immune deficiency syndromes.

[7]  F. Stanczyk,et al.  Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. , 2010, Contraception.

[8]  N. Lakhi,et al.  Implanon® failure in patients on antiretroviral medication: the importance of disclosure , 2010, Journal of Family Planning and Reproductive Health Care.

[9]  J. Petrozzino,et al.  An evidence-based review of treatment-related determinants of patients' nonadherence to HIV medications. , 2009, AIDS patient care and STDs.

[10]  M. Peeters,et al.  Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. , 2009, Contraception.

[11]  L. Bahamondes,et al.  Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. , 2008, Fertility and sterility.

[12]  G. Muirhead,et al.  Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers. , 2008, British journal of clinical pharmacology.

[13]  J. Park,et al.  Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. , 2008, Contraception.

[14]  P. Hogston,et al.  Early contraceptive failure of Implanon® in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz , 2007, Journal of Family Planning and Reproductive Health Care.

[15]  J. Park,et al.  Depo‐medroxyprogesterone in Women on Antiretroviral Therapy: Effective Contraception and Lack of Clinically Significant Interactions , 2007, Clinical pharmacology and therapeutics.

[16]  J. Paavonen,et al.  The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women--effects on bleeding patterns, ovarian function and genital shedding of HIV. , 2006, Human reproduction.

[17]  B. Janowitz,et al.  The Value of Contraception to Prevent Perinatal HIV Transmission , 2006, Sexually transmitted diseases.

[18]  J. Guillebaud Drug interactions with hormonal contraception , 2005, Journal of Family Planning and Reproductive Health Care.

[19]  M. W. van den Heuvel,et al.  Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. , 2005, Contraception.

[20]  W. Haefeli,et al.  Oral contraception does not alter single dose saquinavir pharmacokinetics in women. , 2004, British journal of clinical pharmacology.

[21]  J. Leonard,et al.  Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. , 1998, British journal of clinical pharmacology.

[22]  E. Slaats,et al.  Pulsatile luteinizing hormone secretion during the first and the fourth cycle on two different oral contraceptives containing gestodene. , 1993, Acta endocrinologica.

[23]  V. Mahesh The dynamic interaction between steroids and gonadotropins in the mammalian ovulatory cycle , 1985, Neuroscience & Biobehavioral Reviews.

[24]  J. Baeten,et al.  Use of hormonal contraceptives and risk of HIV-1 transmission : a prospective cohort study , 2011 .

[25]  J. Paavonen,et al.  Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women. , 2007, Contraception.

[26]  I. van der Linde Hormonal contraception and HIV. , 1996, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[27]  F. Guengerich Metabolism of 17 α-ethynylestradiol in humans , 1990 .

[28]  Leon Speroff,et al.  Clinical gynecologic endocrinology and infertility , 1983 .